Screener
Collegium Pharmaceutical, Inc. COLL Jornay PM — 2030
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.
The source filing: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 7:34 AM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-011992
| Years ended December 31, | Jornay PM | Belbuca | Nucynta Products | Symproic | Total |
|---|---|---|---|---|---|
| 2026 | $83,829 | $75,393 | $27,692 | $7,285 | $194,199 |
| 2027 | 83,829 | — | — | 7,285 | 91,114 |
| 2028 | 83,829 | — | — | 7,285 | 91,114 |
| 2029 | 83,829 | — | — | 7,285 | 91,114 |
| 2030 | 83,829 | — | — | 7,285 | 91,114 |
| Thereafter | 104,783 | — | — | 6,072 | 110,855 |
| Remaining amortization expense | $523,928 | $75,393 | $27,692 | $42,497 | $669,510 |
Item 16. Form 10-K Summary
FAQ
- What is Collegium Pharmaceutical, Inc.'s jornay PM — 2030?
- Collegium Pharmaceutical, Inc. (COLL) reported jornay PM — 2030 of $83.83M in Q4 2025.
- What does jornay PM — 2030 mean?
- This metric tracks the financial performance of a specific pharmaceutical asset as it approaches its long-term strategic horizon. It captures the net revenue generation and amortization profile of the product, reflecting its contribution to the company's multi-year growth strategy. This data point is essential for evaluating the product's lifecycle management and its role in the company's future earnings capacity.
Ask your AI about Collegium Pharmaceutical, Inc.'s jornay pm — 2030.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude